O ne fifth of Indigenous infants born in the Northern Territory are hospitalised with an acute lower respiratory infection (ALRI) during their first year of life.
1 Several international studies have reported an inverse relationship between cord blood vitamin D levels and infant respiratory infections.
2-4 As exposure to sunshine is the most important influence on vitamin D status, there has been little consideration of the relationship between vitamin D status and disease in the tropical north of Australia.
Vitamin D is produced in the skin after exposure to sunlight. Subsequent hydroxylation in the liver yields the dominant circulating vitamin D metabolite, 25(OH)D 3 . The discovery that vitamin D receptors are widely distributed throughout human tissues and that several cell types, including those of the immune system, can synthesise the active vitamin D metabolite (1,25(OH) 2 D) from 25(OH)D 3 has prompted renewed interest in the role of vitamin D. Vitamin D is required for innate (antimicrobial peptide production) and adaptive (favours response by T h 2 effector T cells) immune responses. 5 These may be particularly important in the respiratory tract of the developing infant, and perhaps relevant to the relationship between cord blood vitamin D levels and the risk of respiratory infection.
2-4
Circulating 25(OH)D 3 and the less common 25(OH)D 2 are together referred to as 25(OH)D. In the United States, vitamin D deficiency is defined as a serum 25(OH)D level under 50 nmol/L, and vitamin D insufficiency as levels of 50e75 nmol/L. 6 In Australia, 25(OH)D levels of 50 nmol or more are considered sufficient, although higher levels are regarded as optimal. 7 Neonates and breastfed infants rely almost exclusively on maternal vitamin D. 8, 9 According to national population surveys, the prevalence of low 25(OH)D levels (< 50 nmol/L) in women during pregnancy varies from 10% among women in southeast Queensland 10 to more than 80% in dark-skinned and/or veiled women in Melbourne, Victoria. 11 In Far North Queensland, a small study of pregnant women at mid-gestation (93 non-Indigenous and 23 Indigenous women) found that only eight (7%) had 25(OH)D values under 75 nmol/L. 12 While little is known about the vitamin D status of pregnant Indigenous women and children, dark skin is a risk factor for low vitamin D levels, 7 and our recently published data indicate that about 40% of hospitalised Indigenous infants in the NT (median age, 7 months) had 25(OH)D 3 levels below 75 nmol/L. 13 The aims of our study were to describe the natural history of vitamin D status from the third trimester of pregnancy to infancy (age 7 months), and to determine whether low vitamin D levels at birth (cord blood 25(OH)D 3 ) were associated with an increased risk of ALRI hospitalisation during the first year of life. Main outcome measure: ALRI hospitalisations during the first 12 months of infancy, identified using International Classification of Diseases coding (J09eJ22, A37eA37.9).
Methods
Results: Compared with mean 25(OH)D 3 levels in maternal blood during pregnancy (104 nmol/L), mean levels were 23% lower in maternal blood at birth (80 nmol/L) and 48% lower in cord blood samples (54 nmol/L). The mean cord blood 25(OH)D 3 concentration in seven infants subsequently hospitalised for an ALRI was 37 nmol/L (95% CI, 25e48 nmol/L), lower than the 56 nmol/L (95% CI, 51e61 nmol/L) in the 77 infants who were not hospitalised with an ALRI (P ¼ 0.025).
Conclusions: Cord blood 25(OH)D 3 concentrations were about half those in maternal blood during the third trimester of pregnancy (about 7 weeks earlier). Most cord blood levels (80%) were classified as vitamin D insufficient (< 75 nmol/L) by existing guidelines, and were lower among infants who were subsequently hospitalised with an ALRI. 6 and below 50 nmol/L as vitamin D deficiency. 7 
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ALRI hospitalisations
Infant ALRI hospitalisations during the first 12 months of life were identified by International Classification of Diseases, 10th revision, Australian modification (ICD-10-AM) codes recorded during admission to Royal Darwin Hospital (J09eJ22, A37eA37.9). 15 Hospital and study data were linked via the Hospital Registration Number, common to each dataset and unique to each infant. Diagnoses made during the birth admission (ICD-10-AM, Z37.0eZ39.2) and related admissions within 7 days of birth were excluded from the analysis.
Analysis
Vitamin D levels are reported for all available blood samples at each time point. Participant characteristics were assessed according to cord blood vitamin D status categories (< 50 nmol/L, 50e74 nmol/L, ! 75 nmol/L) to assess potential confounders of the exposure. The Fisher exact test (proportional data) and KruskaleWallis test (continuous data) were used to assess differences between groups. The primary analysis was a comparison of cord blood 25(OH)D 3 levels in infants who were subsequently hospitalised with an ALRI with those of infants who were not. Student t tests were used to compare the normally distributed vitamin D data; P < 0.05 (two-tailed) was defined as statistically significant. With 84 cord blood samples and assuming that 20% of infants would be hospitalised with an ALRI 1 and that mean cord blood 25(OH)D 3 levels for healthy infants ranged between 50 and 75 nmol/L (standard deviation, 25 nmol/L), our analysis had 80% power to detect a difference in 25(OH)D 3 levels (between those of infants who were hospitalised for ALRI and of those who were not) of 20 nmol/L. 
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Participant characteristics
In general, participant characteristics were similar across the cord blood 25(OH)D 3 categories, except that remote dwelling was associated with lower cord blood 25(OH)D 3 levels (Box 1). The median maternal age at recruitment was 24 years, and almost half (43%) reported smoking during pregnancy. Uptake of the influenza vaccine during pregnancy was low (14%). Most infants (91%) had received three doses of the pneumococcal conjugate vaccine (PCV; 7-valent or 10-valent plus Haemophilus influenzae protein D) by 12 months of age.
Vitamin D levels
As assessed in maternal venous blood, the prevalence of vitamin D insufficiency was 21% (7 of 
Vitamin D and ALRI hospitalisation
Of the 84 infants for whom cord blood samples were available, seven (8%) were hospitalised with an ALRI during their first 12 months of life; the median age at initial admission was 5.3 months (range, 1.9e7.5 months). In our primary analysis (Box 5), the mean cord blood 25(OH)D 3 concentration in these seven infants was 37 nmol/L (95% CI, 25e48 nmol/L), compared with 56 nmol/L (95% CI, 51e61 nmol/L) for the 77 infants not hospitalised for an ALRI (P ¼ 0.025). Mean 25(OH)D 3 levels in maternal venous blood at birth were similarly lower in the mothers of infants subsequently hospitalised with an ALRI than in the mothers of those not hospitalised for an ALRI (Box 5).
ALRI among urban and remote participants
The proportion of remotely dwelling infants who were hospitalised with an ALRI (4 of 14, 29%) was higher than for urban infants (3 of 70, 4%; P ¼ 0.013). The low number of ALRI hospitalisations was insufficient for a model including remote dwelling as a confounding factor.
Discussion
This is the first study to longitudinally assess vitamin D levels in pregnant Indigenous mothers and their infants. We found that the mean 25(OH)D 3 level in cord blood was about half (48%) that of maternal blood during the third trimester of pregnancy (about 7 weeks earlier), a difference due equally to a decline in maternal levels late in pregnancy and to a gradient across the placenta. We also found that the 25 19 while a study of 14 healthy French women found a 20% decline in mean 25(OH)D 3 levels between 36 weeks' gestation (46.8 nmol/L) and birth (37.4 nmol/L). 20 As there is little seasonal variation in 25(OH)D 3 levels in the tropical NT, 13 the drop in late pregnancy may reflect natural progression, perhaps related to maternalefetal immune tolerance or neonatal immune development, 21 increased calcium demands of the growing fetus, 22 or the emergence of risk factors, such as increased body mass index or more time spent indoors. 7 The cord blood vitamin D data in our study suggest that 80% of infants were born with vitamin D insufficiency (< 75 nmol/L), 44% with mild deficiency (< 50 nmol/L), and 10% with moderate deficiency (< 25 nmol/L). The significance of these definitions for the neonate, however, is unclear, and more work is needed to define vitamin D reference ranges in cord blood. Vitamin D status was generally normal by infant age 7 months, the next sampling point.
Concordant with the trends in our data, a recent trial of maternal-plusinfant vitamin D supplementation for the prevention of deficiency among New Zealand infants 8 showed that mean 25(OH)D levels in the placebo group were higher in mothers at 36 weeks' gestation (50 nmol/L) than in cord blood (33 nmol/L), and that infant levels steadily increased through ages 2 (50 nmol/L), 4 (75 nmol/L) and 6 months (78 nmol/L). As the authors did not report maternal 25(OH)D levels at birth, it was not possible to determine whether the drop between 36 weeks' gestation and cord blood was the result of a maternal decline or of the placental differential. Compliant daily maternal (from 27 weeks' gestation to birth) and infant supplementation (from birth to age 6 months) at low (1000 and 400 IU/day respectively) and high doses (2000 and 800 IU/day respectively) increased mean cord blood 25(OH)D 3 levels to 60 nmol/L and 65 nmol/L respectively (v 33 nmol/L in placebo-treated participants); mean infant 25(OH)D 3 levels of 75 nmol/L or more were maintained at each of the 2, 4 and 6 months sampling points.
Among the participants who contributed a cord blood sample to our study, there were fewer infant ALRI hospitalisations in the first 12 months of life (8%) than predicted by historical NT data (22%).
1 As ALRI hospitalisation rates are highest among remote and Central Australian infants, 1 this difference was probably caused by the Although not all studies support an inverse association between vitamin D levels and ALRI risk, a supplementation strategy beginning in the third trimester of pregnancy may be useful in preventing both vitamin D insufficiency and subsequent acute respiratory infections in Indigenous neonates in the NT. Acute respiratory infections are endemic in remote Indigenous communities because of factors such as overcrowding and exposure to tobacco smoke. 24 However, it is less obvious why remote participants in our study had lower 25(OH)D 3 levels during pregnancy and at birth, or why the relative difference in mean concentrations in maternal blood at 30e36 weeks' gestation and in cord blood was greater than in their urban counterparts (remote, e57% v urban, e48%). Similar vitamin D levels in urban and remote infants at age 7 months suggest that the negative influence of remoteness on vitamin D levels was confined to the mothers. As the climate and time spent outdoors are likely to be similar for urban and remote participants, risk factors other than exposure to sunlight require further investigation. Interestingly, vitamin D has also been found to be a negative acute phase reactant that is depleted after an inflammatory insult. 25 Lower vitamin D levels seen among remote participants may therefore be the result, rather than a cause, of their high burden of infection.
Conclusions
While only one in five Indigenous mothers had 25(OH)D 3 levels below 75 nmol/L midway through the third trimester of their pregnancy, four in five cord bloods tested had lower levels as the result of declining 25(OH)D 3 levels late in pregnancy and differences in levels across the placenta. The significance of low cord blood 25(OH)D 3 concentrations is unclear, but the seven infants hospitalised with an ALRI during their first 12 months of life had significantly lower levels than those not hospitalised with an ALRI. Our findings, in conjunction with emerging international data, support the need for further longitudinal studies and for randomised controlled trials of vitamin D supplementation for the prevention of infant ALRI. 
